JP2008502355A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008502355A5 JP2008502355A5 JP2007526437A JP2007526437A JP2008502355A5 JP 2008502355 A5 JP2008502355 A5 JP 2008502355A5 JP 2007526437 A JP2007526437 A JP 2007526437A JP 2007526437 A JP2007526437 A JP 2007526437A JP 2008502355 A5 JP2008502355 A5 JP 2008502355A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- group
- polypeptide
- ecm
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 17
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 17
- 210000002744 extracellular matrix Anatomy 0.000 claims 17
- 239000003795 chemical substances by application Substances 0.000 claims 13
- 238000000034 method Methods 0.000 claims 12
- 229920001184 polypeptide Polymers 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 230000015556 catabolic process Effects 0.000 claims 9
- 238000006731 degradation reaction Methods 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 108020004459 Small interfering RNA Proteins 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000004055 small Interfering RNA Substances 0.000 claims 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 5
- 108091081021 Sense strand Proteins 0.000 claims 5
- 230000000692 anti-sense effect Effects 0.000 claims 5
- 150000007523 nucleic acids Chemical group 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 230000001575 pathological effect Effects 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 102000053642 Catalytic RNA Human genes 0.000 claims 2
- 108090000994 Catalytic RNA Proteins 0.000 claims 2
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 claims 2
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 claims 2
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 108091092562 ribozyme Proteins 0.000 claims 2
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims 1
- 241000711408 Murine respirovirus Species 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000003150 biochemical marker Substances 0.000 claims 1
- 230000008236 biological pathway Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000002823 phage display Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57930704P | 2004-06-14 | 2004-06-14 | |
| PCT/EP2005/052754 WO2005121778A2 (en) | 2004-06-14 | 2005-06-14 | Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008502355A JP2008502355A (ja) | 2008-01-31 |
| JP2008502355A5 true JP2008502355A5 (OSRAM) | 2009-04-30 |
Family
ID=35503767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007526437A Pending JP2008502355A (ja) | 2004-06-14 | 2005-06-14 | 変性性及び炎症性疾患の治療に役立つ同定方法及び化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7306923B2 (OSRAM) |
| EP (4) | EP2270160A1 (OSRAM) |
| JP (1) | JP2008502355A (OSRAM) |
| AT (1) | ATE534736T1 (OSRAM) |
| CA (1) | CA2569511A1 (OSRAM) |
| MX (1) | MXPA06014577A (OSRAM) |
| WO (1) | WO2005121778A2 (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7485468B2 (en) * | 2004-10-15 | 2009-02-03 | Galapagos Bv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases |
| WO2007071048A1 (en) * | 2005-12-22 | 2007-06-28 | Jane Ennis | Viable cells from frozen umbilical cord tissue |
| MX2009013766A (es) | 2007-06-20 | 2010-02-01 | Galapagos Nv | Objetivos moleculares y compuestos, y metodos para identificar los mismos, utiles en el tratamiento de enfermedades degenerativas de los huesos y las articulaciones. |
| WO2009036368A2 (en) | 2007-09-14 | 2009-03-19 | Nitto Denko Corporation | Drug carriers |
| US8450397B2 (en) * | 2007-09-25 | 2013-05-28 | Dunlop Sports Co. Ltd. | Golf ball |
| DE102007059839A1 (de) | 2007-12-11 | 2009-06-25 | Harald Dipl.-Ing. Feuerherm | Schlauchförmiger Vorformling und Herstellung blasgeformter Teile und Verfahren sowie Vorrichtung zur Herstellung des Vorformlings |
| AU2009295575B2 (en) | 2008-09-24 | 2015-11-05 | Tel Hashomer Medical Research, Infrastructure And Services Ltd. | Peptides and compositions for prevention of cell adhesion and methods of using same |
| US11174299B2 (en) | 2008-12-29 | 2021-11-16 | Dispersebio Ltd. | Peptides and compositions for prevention of cell adhesion and methods of using same |
| US8552147B2 (en) | 2008-12-29 | 2013-10-08 | Tel Hashomer Medical Research, Infrastructure And Services Ltd. | Peptides and compositions for prevention of cell adhesion and methods of using same |
| AU2015224504B2 (en) * | 2008-12-29 | 2018-02-22 | Tel Hashomer Medical Research, Infrastructure And Services Ltd | Peptides and compositions for prevention of cell adhesion and methods of using same |
| EP3043179B1 (en) * | 2009-04-01 | 2020-05-06 | Galapagos N.V. | Methods and means for treatment of osteoarthritis |
| AU2013216983A1 (en) | 2012-02-07 | 2014-09-18 | La Jolla Institute For Allergy And Immunology | Epitopes from allergen proteins and methods and uses for immune response modulation |
| US20160138027A1 (en) * | 2013-03-14 | 2016-05-19 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1) |
| CN111194355A (zh) * | 2017-09-13 | 2020-05-22 | 亚历克塞拉公司 | 用于鉴定与stk24相互作用的治疗剂的方法 |
| WO2021146386A1 (en) * | 2020-01-14 | 2021-07-22 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for targeted protein stabilization by redirecting endogenous deubiquitinases |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5354844A (en) | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
| US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| JPH07509133A (ja) | 1992-07-17 | 1995-10-12 | リボザイム・ファーマシューティカルズ・インコーポレイテッド | 動物疾患の処置のための方法および剤 |
| FR2714830B1 (fr) | 1994-01-10 | 1996-03-22 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| FR2715847B1 (fr) | 1994-02-08 | 1996-04-12 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| FR2727679B1 (fr) | 1994-12-05 | 1997-01-03 | Rhone Poulenc Rorer Sa | Nouveaux agents de transfection et leurs applications pharmaceutiques |
| FR2730637B1 (fr) | 1995-02-17 | 1997-03-28 | Rhone Poulenc Rorer Sa | Composition pharmaceutique contenant des acides nucleiques, et ses utilisations |
| WO1999038980A2 (en) | 1998-01-29 | 1999-08-05 | The Board Of Regents Of The University Of Oklahoma | Tyrosylprotein sulfotransferase polypeptides and polynucleotides |
| WO2000014250A1 (en) | 1998-09-09 | 2000-03-16 | The Board Of Regents Of The University Of Oklahoma | Tyrosylprotein sulfotransferase polypeptides and polynucleotides |
| ATE346147T1 (de) * | 1998-02-13 | 2006-12-15 | Wistar Inst | Zusammensetzungen und methoden zur wundheilung |
| US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
| US20020151681A1 (en) * | 1999-03-12 | 2002-10-17 | Rosen Craig A. | Nucleic acids, proteins and antibodies |
| US20050112118A1 (en) * | 1999-12-02 | 2005-05-26 | Myriad Genetics, Incorporated | Compositions and methods for treating inflammatory disorders |
| US7332337B2 (en) | 2000-05-16 | 2008-02-19 | Galapagos Nv | Viral vectors having tissue tropism for T-lymphocytes, B- and mast cells |
| US7235233B2 (en) | 2000-09-26 | 2007-06-26 | Crucell Holland B.V. | Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts |
| US20020132823A1 (en) | 2001-01-17 | 2002-09-19 | Jiahuai Han | Assay method |
| AU2002253104A1 (en) | 2001-03-07 | 2002-09-19 | Galapagos Genomics B.V. | Adenoviral library assay for e2f regulatory genes and methods and compositions for screening compounds |
| US6537780B2 (en) | 2001-03-28 | 2003-03-25 | Applera Corporation | Isolated nucleic acid molecules encoding transferase enzymes |
| US6426221B1 (en) * | 2001-08-01 | 2002-07-30 | Isis Pharmaceuticals, Inc. | Antisense modulation of RIP2 expression |
| US20030198627A1 (en) | 2001-09-01 | 2003-10-23 | Gert-Jan Arts | siRNA knockout assay method and constructs |
| AU2003225535A1 (en) * | 2002-01-31 | 2003-09-02 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating cancer |
| CA2498274A1 (en) * | 2002-09-16 | 2004-03-25 | Genentech, Inc. | Compositions and methods for the diagnosis of immune related diseases using pro7 |
| AU2003286711A1 (en) | 2002-10-25 | 2004-05-13 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
| JP2006515747A (ja) * | 2002-11-01 | 2006-06-08 | ジェネンテック・インコーポレーテッド | 免疫関連疾患の治療のための組成物と方法 |
| EP1588163A2 (en) * | 2003-01-23 | 2005-10-26 | Eirx Therapeutics Ltd | Kinases and gpcrs involved in apoptosis |
| WO2004092413A2 (en) * | 2003-04-18 | 2004-10-28 | Novartis Ag | High throughput functional genomic screening methods for osteoarthritis |
| WO2004094636A1 (en) | 2003-04-24 | 2004-11-04 | Galapagos Genomics N.V. | Effective sirna knock-down constructs |
| DE10328033A1 (de) | 2003-06-19 | 2005-01-05 | Bläß, Stefan, Dr. | Verfahren und ArthritisChip zur Diagnostik, Verlaufskontrolle sowie zur Charakterisierung der rheumatoiden Arthritis und der Osteoarthrose |
| CA2533803A1 (en) * | 2003-07-29 | 2005-02-10 | Bristol-Myers Squibb Company | Biomarkers of cyclin-dependent kinase modulation |
| US7485468B2 (en) * | 2004-10-15 | 2009-02-03 | Galapagos Bv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases |
-
2005
- 2005-06-14 WO PCT/EP2005/052754 patent/WO2005121778A2/en not_active Ceased
- 2005-06-14 JP JP2007526437A patent/JP2008502355A/ja active Pending
- 2005-06-14 AT AT05774134T patent/ATE534736T1/de active
- 2005-06-14 US US11/152,366 patent/US7306923B2/en not_active Expired - Fee Related
- 2005-06-14 EP EP10174541A patent/EP2270160A1/en not_active Withdrawn
- 2005-06-14 EP EP10174544A patent/EP2256198A1/en not_active Withdrawn
- 2005-06-14 MX MXPA06014577A patent/MXPA06014577A/es active IP Right Grant
- 2005-06-14 CA CA002569511A patent/CA2569511A1/en not_active Abandoned
- 2005-06-14 EP EP05774134A patent/EP1773997B1/en not_active Expired - Lifetime
- 2005-06-14 EP EP10174539A patent/EP2256197A1/en not_active Withdrawn
-
2007
- 2007-09-12 US US11/854,037 patent/US7919259B2/en not_active Expired - Fee Related
-
2011
- 2011-02-01 US US13/019,142 patent/US20110118140A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008516593A5 (OSRAM) | ||
| JP7079761B2 (ja) | 心不全の治療のための標的としてのｂａｇ３ | |
| JP2008502355A5 (OSRAM) | ||
| JP2008503712A5 (OSRAM) | ||
| JP2007534725A5 (OSRAM) | ||
| JP6437467B2 (ja) | 線維化疾患治療において有用な分子標的及び化合物、並びにこれらの同定方法 | |
| US8663936B2 (en) | Sodium channel protein type III α-subunit splice variant | |
| JP2016522675A (ja) | 上皮間葉移行に関連した疾患の治療において有用な分子標的及び前記標的のインヒビター | |
| JP2012517822A (ja) | 炎症を包含する疾患の診断及び治療に有用な同定方法及び化合物 | |
| US7125676B2 (en) | Expression system for human brain-specific voltage-gated sodium channel, type 1 | |
| EP2210112B1 (en) | Diagnostic methods for hiv infection | |
| WO2005121778B1 (en) | Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseases | |
| JP2019524740A (ja) | Ｃｒｅｂｂｐ関連癌の治療法 | |
| JP7177439B2 (ja) | 炎症促進因子発現抑制剤、その有効成分のスクリーニング方法、該方法に有用な発現カセット、診断薬、及び診断方法 | |
| JP2007533989A5 (OSRAM) | ||
| JP2005507648A5 (OSRAM) | ||
| US20110077283A1 (en) | Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases | |
| EP2795337B1 (en) | Screening methods to identify compounds useful in the prevention and/or treatment of inflammatory conditions | |
| US20110293635A1 (en) | Composition and methods for modulating toll-like receptor activity | |
| JP2009502732A5 (OSRAM) | ||
| JP2012518181A (ja) | 炎症を包含する疾患の診断及び治療に有用な同定方法及び化合物 | |
| WO2016170022A1 (en) | Therapeutic methods, products and compositions inhibiting znf555 | |
| JP7325075B2 (ja) | フリズルド３発現細胞の細胞数増加剤若しくは低下剤、糖尿病予防若しくは治療剤、インスリノーマ予防若しくは治療剤、及びインスリン分泌促進剤若しくは分泌抑制剤よりなる群から選択される少なくとも１つの剤をスクリーニングするためのスクリーニング剤、スクリーニング用キット、及びスクリーニング方法 | |
| JP2005503123A5 (OSRAM) | ||
| JP2006516888A5 (OSRAM) |